Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3627-3630

  Zelenitsky, Sheryl ^a,c   Alkurdi, Noha ^b   Weber, Zhanni ^a   Ariano, Robert ^a,c   Zhanel, George ^a,b,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

^d HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BROTH DILUTION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 79959249660     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01472-10     Document Type: Article

References (33)

1. Berthoin, K., E. Ampe, P. M. Tulkens, and S. Carryn. 2009. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int. J. Antimicrob. Agents 34:555-560.
2. Bowker, K. E., A. R. Noel, and A. P. MacGowan. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J. Antimicrob. Chemother. 64:1044-1051.
3. Chua, K., and B. P. Howden. 2009. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. Curr. Opin. Infect. Dis. 22:525-534.
4. Harigaya, Y., et al. 2009. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob. Agents Chemother. 53:3894-3901.
5. Hazlewood, K. A., S. D. Brouse, W. D. Pitcher, and R. G. Hall. 2010. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am. J. Med. 123:182.e1-182.e7.
6. Howden, B. P., J. K. Davies, P. D. Johnson, T. P. Stinear, and M. L. Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
7. Hutschala, D., et al. 2009. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 111:356-365.
8. Ingram, P. R., D. C. Lye, D. A. Fisher, W. P. Goh, and V. H. Tam. 2009. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int. J. Antimicrob. Agents 34:570-574.
9. Lodise, T. P., et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
10. Lodise, T. P., B. Lomaestro, J. Graves, and G. L. Drusano. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52:1330-1336.
11. Lodise, T. P., et al. 2008. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 62:1138-1141.
12. Lodise, T. P., N. Patel, B. M. Lomaestro, K. A. Rodvold, and G. L. Drusano. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
13. Moise, P. A., et al. 2008. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 61:85-90.
14. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.
15. Moise-Broder, P. A., et al. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705.
16. Musta, A. C., et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
17. Pea, F., et al. 2009. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob. Agents Chemother. 53:1863-1867.
18. Roberts, J. A., J. Lipman, S. Blot, and J. Rello. 2008. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr. Opin. Crit. Care 14:390-396.
19. Rose, W. E., R. M. Knier, and P. R. Hutson. 2010. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 65:2149-2154.
20. Rose, W. E., S. N. Leonard, K. L. Rossi, G. W. Kaatz, and M. J. Rybak. 2009. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 53:805-807.
21. Rose, W. E., M. J. Rybak, B. T. Tsuji, G. W. Kaatz, and G. Sakoulas. 2007. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J. Antimicrob. Chemother. 59:1190-1193.
22. Rybak, M., et al. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
23. Sader, H. S., P. R. Rhomberg, and R. N. Jones. 2009. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:3162-3165.
24. Sakoulas, G., et al. 2005. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob. Agents Chemother. 49:2687-2692.
25. Sakoulas, G., et al. 2003. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. 187:929-938.
26. Sakoulas, G., et al. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502.
27. Sakoulas, G., R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1):S40-S50.
28. Soriano, A., et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
29. Tenover, F. C., and R. C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215.
30. Tsuji, B. T., Y. Harigaya, A. J. Lesse, G. Sakoulas, and J. M. Mylotte. 2009. Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Diagn. Microbiol. Infect. Dis. 64:220-224.
31. Tsuji, B. T., M. J. Rybak, K. L. Lau, and G. Sakoulas. 2007. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:1089-1091.
32. Walsh, T. R., et al. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
33. Wysocki, M., et al. 1995. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J. Antimicrob. Chemother. 35:352-354.